"Cell Line, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell line derived from cultured tumor cells.
| Descriptor ID |
D045744
|
| MeSH Number(s) |
A11.251.210.190 A11.251.860.180
|
| Concept/Terms |
Cell Line, Tumor- Cell Line, Tumor
- Cell Lines, Tumor
- Line, Tumor Cell
- Lines, Tumor Cell
- Tumor Cell Lines
- Tumor Cell Line
|
Below are MeSH descriptors whose meaning is more general than "Cell Line, Tumor".
Below are MeSH descriptors whose meaning is more specific than "Cell Line, Tumor".
This graph shows the total number of publications written about "Cell Line, Tumor" by people in this website by year, and whether "Cell Line, Tumor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 31 | 31 |
| 2004 | 0 | 60 | 60 |
| 2005 | 1 | 63 | 64 |
| 2006 | 0 | 66 | 66 |
| 2007 | 0 | 89 | 89 |
| 2008 | 0 | 77 | 77 |
| 2009 | 1 | 95 | 96 |
| 2010 | 1 | 106 | 107 |
| 2011 | 0 | 88 | 88 |
| 2012 | 1 | 110 | 111 |
| 2013 | 0 | 109 | 109 |
| 2014 | 0 | 126 | 126 |
| 2015 | 0 | 116 | 116 |
| 2016 | 0 | 107 | 107 |
| 2017 | 0 | 94 | 94 |
| 2018 | 0 | 87 | 87 |
| 2019 | 1 | 83 | 84 |
| 2020 | 0 | 64 | 64 |
| 2021 | 0 | 67 | 67 |
| 2022 | 0 | 19 | 19 |
| 2023 | 0 | 26 | 26 |
| 2024 | 0 | 38 | 38 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cell Line, Tumor" by people in Profiles.
-
Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance. Clin Cancer Res. 2024 Oct 01; 30(19):4450-4463.
-
NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs. Cancer Immunol Res. 2024 Oct 01; 12(10):1421-1437.
-
Enhancing carboplatin sensitivity in ovarian cancer cells by blocking the mercapturic acid pathway transporter. Carcinogenesis. 2024 Sep 11; 45(9):696-707.
-
NKG2C/KLRC2 tumor cell expression enhances immunotherapeutic efficacy against glioblastoma. J Immunother Cancer. 2024 Aug 30; 12(8).
-
IGF2BP3 promotes mRNA degradation through internal m7G modification. Nat Commun. 2024 Aug 28; 15(1):7421.
-
RNA interacts with topoisomerase I to adjust DNA topology. Mol Cell. 2024 Sep 05; 84(17):3192-3208.e11.
-
A Glutathione-Consuming Bimetallic Nano-Bomb with the Combination of Photothermal and Chemodynamic Therapy for Tumors: An in vivo and in vitro Study. Int J Nanomedicine. 2024; 19:8541-8553.
-
Venetoclax Induces BCL-2-Dependent Treg to TH17 Plasticity to Enhance the Antitumor Efficacy of Anti-PD-1 Checkpoint Blockade. Cancer Immunol Res. 2024 Aug 01; 12(8):1074-1089.
-
Exploring markers of immunoresponsiveness in papillary thyroid carcinoma and future treatment strategies. J Immunother Cancer. 2024 Jul 29; 12(7).
-
Carcinoma-associated mesenchymal stem cells promote ovarian cancer heterogeneity and metastasis through mitochondrial transfer. Cell Rep. 2024 Aug 27; 43(8):114551.